PharmaTher Holdings Ltd. is a specialty psychedelic pharmaceutical company, which engages in the research, development and commercialization of ketamine and novel microneedle patches for delivering psychedelics to treat neuropsychiatric, neurodegenerative, and pain disorders. The company is headquartered in Toronto, Ontario. The company went IPO on 2020-10-09. The firm develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The firm is also commercializing PharmaPatch (microneedle patch) with its partners to deliver psychedelics and drugs to treat infectious diseases. The firm is in the development of programs for the delivery of KETARX (ketamine) in a patch and on-body pump for mental health, pain and medical countermeasures indications.
How did PHRRF's recent EPS compare to expectations?
The most recent EPS for PharmaTher Holdings Ltd. is $, expectations of $.
How did PharmaTher Holdings Ltd. PHRRF's revenue perform in the last quarter?
PharmaTher Holdings Ltd. revenue for the last quarter is $
What is the revenue estimate for PharmaTher Holdings Ltd.?
According to of Wall street analyst, the revenue estimate of PharmaTher Holdings Ltd. range from $ to $
What's the earning quality score for PharmaTher Holdings Ltd.?
PharmaTher Holdings Ltd. has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does PharmaTher Holdings Ltd. report earnings?
PharmaTher Holdings Ltd. next earnings report is expected in 2026-04-29
What are PharmaTher Holdings Ltd.'s expected earnings?
PharmaTher Holdings Ltd. expected earnings is $, according to wall-street analysts.
Did PharmaTher Holdings Ltd. beat earnings expectations?
PharmaTher Holdings Ltd. recent earnings of $ expectations.